Jaguar Health, Inc. (JAGX) Latest Company News

Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. agreed to issue 535,000 shares of common stock and a pre-funded warrant for 2,077,255 shares to Joshua Mailman in exchange for all of his shares of Napo Therapeutics S.p.A., closing on September 15, 2026.
Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. issued 31,847 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 0.4 shares of Series Q Perpetual Preferred Stock.
Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. issued 219,435 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 2.8 shares of Series Q Perpetual Preferred Stock.
Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. issued 557,377 shares of common stock to Lincoln Alternative Strategies LLC in exchange for cancellation of the $175,016.36 outstanding balance on a 6% convertible promissory note.
Sep 15, 2026, 13:00 UTC
Jaguar Health, Inc. announced a 1-for-15 reverse stock split of its common stock, effective September 17, 2026, to support compliance with Nasdaq listing standards.
Source:
- accessnewswire.com
Sep 10, 2026, 13:00 UTC
Napo Pharmaceuticals, a Jaguar Health family company, announced that all randomized pediatric MVID patients in its pivotal crossover clinical trial have entered the single-blind extension phase to receive blinded doses of crofelemer, supporting plans to file an NDA in mid-2027.
Source:
- accessnewswire.com
Aug 26, 2026, 13:00 UTC
Jaguar Health initiated the commercial launch of Neonorm Dog, a non-prescription plant-based product for dogs, and plans to make it available through Amazon and Chewy soon.
Source:
- accessnewswire.com
Aug 19, 2026, 00:00 UTC
Jaguar Health reported Q2 2026 revenue of $1.225 million, down 59% year-over-year, with a net loss of $12.69 million and diluted EPS of -$15.68.
Source:
- seekingalpha.com
Aug 5, 2026, 13:00 UTC
Jaguar Health satisfied the conditions to receive a $2 million holdback payment from Future Pak under its U.S. commercial licensing agreement for Mytesi and Canalevia-CA1.
Source:
- accessnewswire.com
Jul 22, 2026, 13:00 UTC
Jaguar Health's subsidiary Napo Pharmaceuticals is providing crofelemer powder for oral solution to an additional infant patient in the European Union for compassionate use treatment of intestinal failure due to microvillus inclusion disease.
Source:
- accessnewswire.com
- accessnewswire.com
Jun 25, 2026, 00:00 UTC
Jaguar Health and its subsidiary Napo Pharmaceuticals amended their Manufacturing and Supply Agreement with Woodward Specialty LLC, clarifying inventory title transfer rules and establishing a temporary inventory management arrangement.
Jun 22, 2026, 13:00 UTC
Jaguar Health's Board of Directors initiated a process to explore strategic alternatives to maximize stockholder value, aligned with its planned NDA filing for a rare disease intestinal failure program.
Source:
- accessnewswire.com
Jun 11, 2026, 00:00 UTC
Jaguar Health, Inc. signed a $40 million common stock equity line of credit (ELOC) offering agreement with C/M Capital Partners, LP on June 9, 2026.
Jun 2, 2026, 00:00 UTC
Jaguar Health, Inc. issued 31,958 shares of common stock to Streeterville Capital, LLC in exchange for 3.72 outstanding shares of Series Q Perpetual Preferred Stock on May 26, 2026.

JAGX

Jaguar Health, Inc. agreed to issue 535,000 shares of common stock and a pre-funded warrant for 2,077,255 shares to Joshua Mailman in exchange for all of his shares of Napo Therapeutics S.p.A., closing on September 15, 2026.

Jaguar Health, Inc. issued 31,847 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 0.4 shares of Series Q Perpetual Preferred Stock.

Jaguar Health, Inc. issued 219,435 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 2.8 shares of Series Q Perpetual Preferred Stock.

Jaguar Health, Inc. issued 557,377 shares of common stock to Lincoln Alternative Strategies LLC in exchange for cancellation of the $175,016.36 outstanding balance on a 6% convertible promissory note.

Jaguar Health, Inc. announced a 1-for-15 reverse stock split of its common stock, effective September 17, 2026, to support compliance with Nasdaq listing standards.

Napo Pharmaceuticals, a Jaguar Health family company, announced that all randomized pediatric MVID patients in its pivotal crossover clinical trial have entered the single-blind extension phase to receive blinded doses of crofelemer, supporting plans to file an NDA in mid-2027.

Jaguar Health initiated the commercial launch of Neonorm Dog, a non-prescription plant-based product for dogs, and plans to make it available through Amazon and Chewy soon.

Jaguar Health reported Q2 2026 revenue of $1.225 million, down 59% year-over-year, with a net loss of $12.69 million and diluted EPS of -$15.68.

Jaguar Health satisfied the conditions to receive a $2 million holdback payment from Future Pak under its U.S. commercial licensing agreement for Mytesi and Canalevia-CA1.

Jaguar Health's subsidiary Napo Pharmaceuticals is providing crofelemer powder for oral solution to an additional infant patient in the European Union for compassionate use treatment of intestinal failure due to microvillus inclusion disease.

Jaguar Health and its subsidiary Napo Pharmaceuticals amended their Manufacturing and Supply Agreement with Woodward Specialty LLC, clarifying inventory title transfer rules and establishing a temporary inventory management arrangement.

Jaguar Health's Board of Directors initiated a process to explore strategic alternatives to maximize stockholder value, aligned with its planned NDA filing for a rare disease intestinal failure program.

Jaguar Health, Inc. signed a $40 million common stock equity line of credit (ELOC) offering agreement with C/M Capital Partners, LP on June 9, 2026.

Jaguar Health, Inc. issued 31,958 shares of common stock to Streeterville Capital, LLC in exchange for 3.72 outstanding shares of Series Q Perpetual Preferred Stock on May 26, 2026.